Skip to main content

Table 2 The proportion of CLDN18.2 moderate-to-strong expression in clinical, pathological, and molecular subtypes

From: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer

Characteristic

TC region

P value

Normal region

P value

Age

 < 60

0.408

0.64

0.499

0.75

 ≥ 60

0.434

0.471

Gender

 Male

0.446

0.10

0.468

0.48

 Female

0.344

0.524

ECOG PS

 0

0.431

0.68

0.481

0.98

 1

0.408

0.483

Location

 GEJ

0.501

0.051

0.642

0.015

 Non-GEJ

0.388

0.442

Lauren classification

 Intestinal type

0.382

0.36

0.468

0.62

 Diffused type

0.463

0.558

 Mixed type

0.454

0.448

Stage

 I–II

0.283

0.028

0.371

0.20

 III–IV

0.446

0.510

Differentiation

 Moderate

0.303

0.015

0.488

0.042

 Moderate-poor

0.453

0.337

 Poor

0.480

0.586

HER2 expression

 Positive

0.395

0.54

0.510

0.67

 Negative

0.432

0.471

PD-L1 expression (CPS)

 ≤ 5

0.402

0.53

0.465

0.71

 >5

0.436

0.497

MMR status

 pMMR

0.427

0.62

0.498

0.40

 dMMR

0.388

0.335

EBV status

 Positive

0.526

0.14

0.445

0.74

 Negative

0.407

0.489

  1. Abbreviations: IQR interquartile range, GEJ gastroesophageal junction, dMMR deficient mismatch repair, pMMR proficient mismatch repair